EQRx

Orbital shows 2023’s venture funding scene is far from stratospheric
Orbital shows 2023’s venture funding scene is far from stratospheric
EP Vantage
RNA
funding
venture capital
Altos Labs
CureVac
EQRx
Hasten Biopharmaceutic
Orbital Therapeutics
Sana Biotechnology
Suzhou Abogen Biosciences
TORL BioTherapeutics
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
Endpoints
ASCO 2022
CG Oncology
Merck
Keytruda
EQRx
sugemalimab
Flag link:
Biotech's top 10 money raisers of 2021
Biotech's top 10 money raisers of 2021
Fierce Biotech
biotech
funding
Abogen
Elevate Bio
EQRx
Neumora
Laronde Therapeutics
Adagio Therapeutics
Sotio
Altos Labs
Sonoma Biotherapeutics
Insilico
Flag link:
EQRx adds armor to its discount checkpoint inhibitor submission, nailing survival mark in key study
EQRx adds armor to its discount checkpoint inhibitor submission, nailing survival mark in key study
Endpoints
EQRx
CStone Pharmaceuticals
sugemalimab
Flag link:
EQRX aims for biopharma SPAC record
EQRX aims for biopharma SPAC record
EP Vantage
SPAC
EQRx
Flag link:
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs: a look ahead at ASCO
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs: a look ahead at ASCO
BioPharma Dive
ASCO 2021
Allogene
CAR-T
Bristol Myers Squibb
EQRx
Flag link:
Cut-price drug venture takes aim at Pfizer and Astrazeneca
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EP Vantage
Pfizer
AstraZeneca
EQRx
drug pricing
Ibrance
Tagrisso
Flag link:
A Pharma Startup Launches With $200 Million In Funding And A Strategy To Make Drugs Faster, Cheaper
A Pharma Startup Launches With $200 Million In Funding And A Strategy To Make Drugs Faster, Cheaper
Forbes
drug pricing
EQRx
Alex Borisy
Flag link: